Preferred Label : Atigotatug/Nivolumab;
NCIt synonyms : BMS-986012 Plus Nivolumab Fixed Dose Combination; Atigotatug-Nivolumab; Atigotatug and Nivolumab;
NCIt definition : A fixed-dose combination formulation composed of atigotatug, a human immunoglobulin
G1 (IgG1) monoclonal antibody directed against the ganglioside fucosyl-GM1, and nivolumab,
a human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative
immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with
immune checkpoint inhibitory and antineoplastic activities. Upon administration of
atigotatug/nivolumab, atigotatug binds to fucosyl-GM1 on cancer cells and may activate
both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity
(CDC) against the bound tumor cells. This may inhibit the proliferation of GM1-expressing
tumor cells. Nivolumab binds to and blocks the activation of PD-1 by its ligands programmed
cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), which is overexpressed
on certain cancer cells, and programmed cell death-1 ligand 2 (PD-L2; cluster of differentiation
273; CD273), which is primarily expressed on antigen-presenting cells (APCs). This
prevents PD-1-mediated signaling and PD-1-mediated inhibition of the immune response,
and results in the activation of T-cells and cell-mediated immune responses against
tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key
role in tumor evasion from host immunity. Fucosyl-GM1, a sphingolipid monosialoganglioside
and tumor associated antigen (TAA), is overexpressed on the surface of many cancer
cells while its expression is minimal or non-existent in normal tissues.;
Molecule name : BMS 986489; BMS-986489;
Origin ID : C217158;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
